✨ Free AI Report
Athira Pharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Athira Pharma, Inc.
Company Research

Athira Pharma, Inc.: Business Overview, Financials & Competitive Analysis

Athira Pharma, Inc.: A Comprehensive Overview Athira Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases such as...

Analyst-debate audio for Athira Pharma, Inc.

AskCyborg analysts argue the bull and bear cases for Athira Pharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Product PortfolioATH-1017Leadership and Management TeamLeen Kawas, Ph.D. – President and CEODr. Hans Moebius – Chief Medical OfficerFinancial Overview of Athira Pharma, Inc.
Get Interactive Report Freeor start reading below
Live on AskCyborg
4/10Challenged
Athira Pharma, Inc.

Early-stage neurodegenerative disease biotech at inflection point with viable pipeline but severe capital constraints and reputational headwinds requiring strategic combination.

▶︎ Listen to the 90-second analyst debate
4/ 10Challenged

Cyborg Score thesis

Early-stage neurodegenerative disease biotech at inflection point with viable pipeline but severe capital constraints and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Athira Pharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Athira Pharma, Inc.: A Comprehensive Overview

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Founded in 2011 and headquartered in Bothell, Washington, Athira Pharma, Inc. has quickly emerged as a leader in the field of neuroscience, driven by a mission to restore neuronal health and improve clinical outcomes for patients suffering from neurological disorders.

Product Portfolio

Pro stress-test →

Athira Pharma, Inc.’s product portfolio focuses primarily on regenerative therapies aimed at treating neurodegenerative diseases. The company’s lead product candidate, ATH-1017, is an investigational small molecule designed to enhance neurotrophic signaling and promote neuronal health. This promising drug is currently undergoing clinical trials and has shown potential in improving cognitive function and slowing disease progression.

ATH-1017

Pro stress-test →

ATH-1017 is designed to activate HGF/MET, a critical pathway for neuronal health and repair. By targeting this pathway, ATH-1017 aims to improve cognitive function in patients with Alzheimer’s disease and other neurodegenerative conditions.

Leadership and Management Team

Pro stress-test →

Athira Pharma, Inc. is led by a team of experienced professionals with deep expertise in neuroscience, drug development, and business management.

Leen Kawas, Ph.D. – President and CEO

Dr. Kawas is a co-founder of the company and has been instrumental in driving its vision and strategy. Under her leadership, Athira has secured significant funding and advanced its clinical programs.

Dr. Hans Moebius – Chief Medical Officer

With over 30 years of experience in neuroscience and clinical development, Dr. Moebius oversees Athira’s clinical strategy and execution.

Financial Overview of Athira Pharma, Inc.

Athira Pharma, Inc. has demonstrated strong financial performance, driven by successful funding rounds and strategic partnerships. The company went public in 2020, raising significant capital to support its clinical programs. Key financial metrics include:

  • Market Capitalization: Approximately $500 million.
  • Annual Revenue: Primarily from grants and research collaborations.
  • Research and Development Expenses: Significant investment in clinical trials and drug development.

Marketing Strategies

Athira Pharma, Inc. employs a targeted marketing strategy aimed at raising awareness about its innovative therapies among key stakeholders, including healthcare professionals, patients, and investors. The company leverages digital marketing, scientific publications, and industry conferences to disseminate information about its clinical progress and therapeutic potential.

Athira Pharma, Inc. Market Research

The market for neurodegenerative disease treatments is highly competitive, with several major players, including Biogen, Eli Lilly, and Roche, investing heavily in research and development. Athira Pharma, Inc. differentiates itself through its unique approach to targeting neurotrophic pathways and its focus on regenerative therapies.

Sales Strategies

Athira Pharma, Inc. leverages a multi-channel sales strategy to reach its target market. This includes partnerships with academic institutions, collaborations with pharmaceutical companies, and direct engagement with healthcare providers. The company’s sales strategy is designed to maximize the reach and impact of its innovative therapies.

Technologies Utilized

Athira Pharma, Inc. employs cutting-edge technologies in its drug development process. This includes advanced molecular biology techniques, high-throughput screening, and sophisticated data analytics to identify and optimize therapeutic candidates. The company’s innovative approach has enabled it to rapidly advance its clinical programs and bring novel therapies to market.

HR Practices

Athira Pharma, Inc. is committed to fostering a collaborative and inclusive work environment. The company offers competitive compensation packages, comprehensive benefits, and opportunities for professional development. Athira also values diversity and inclusion, recognizing that a diverse workforce drives innovation and better decision-making.

Corporate Responsibility

Athira Pharma, Inc. is dedicated to corporate social responsibility, with initiatives focused on patient advocacy, scientific education, and community engagement. The company partners with patient organizations to raise awareness about neurodegenerative diseases and support those affected by these conditions.

Future Plans

Looking ahead, Athira Pharma, Inc. aims to advance its clinical programs and bring its innovative therapies to market. The company is focused on completing the clinical development of ATH-1017 and exploring additional indications for its therapeutic candidates. Athira also plans to expand its research pipeline and explore new areas of neuroscience to address unmet medical needs.


Get the full Athira Pharma, Inc. Research Report by subscribing

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Athira Pharma, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Athira Pharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare Athira Pharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Athira Pharma, Inc. operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus research →
NEW · MCP server

Ask your AI assistant about Athira Pharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Athira Pharma, Inc. and its top competitor on Cyborg Score”
“What did Athira Pharma, Inc. do this quarter?”
“Is Athira Pharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Athira Pharma, Inc. do?+
Athira Pharma, Inc.: A Comprehensive Overview Athira Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases such as...
What is Athira Pharma, Inc.'s Cyborg Score?+
Athira Pharma, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Athira Pharma, Inc.'s main competitors?+
Named competitors include Cassava Sciences, Cognition Therapeutics, Quince Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Athira Pharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Athira Pharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Athira Pharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed